Imagine a revolving door for medicine. Instead of nurses manually switching tubes and risking a dangerous mix of chemicals, this valve ensures only one drug flows at a time. It acts like a physical lock that prevents incompatible medicines from meeting in the patient's vein. It also keeps hazardous drugs sealed away from the nurse's skin.
Nurses risk health complications and patients risk severe adverse events when incompatible drugs are accidentally mixed during IV infusion due to human error.
A two-part turn valve (house and handle) made by injection moulded plastic, including a multicavity mould tool for mass production.
If you are an IV set manufacturer dealing with the need for safer drug delivery systems — this project developed a turn-valve component that allows sequential administration of up to 6 drugs. This adds a high-value safety feature to your product portfolio to attract hospitals.
If you are a hospital dealing with human error in drug administration and nurse safety — this project developed a Closed System Valve that minimizes hazardous drug exposure. This could reduce the risk for the 7.3 M nurses exposed to hazardous drugs in Europe annually.
If you are a clinic dealing with complex multi-drug protocols — this project developed a device where all drugs are connected at the start. This makes the procedure more time-efficient and eliminates the risk of parallel flow of incompatible drugs.
The project developed a multicavity injection mould tool which has drastically reduced the cost of goods (COGS).
Yes, the project focused on scalability by increasing the automation level in production and developing a multicavity mould tool.
Based on available project data, the device is developed by CYTO365 AB, but specific licensing terms are not detailed.
The house part is manufactured with tight tolerances to be compliant with the Luer standard.
It acts as a Closed System Valve (CSV) that minimizes hazardous drug exposure for nurses, potentially reducing cases of leukaemia and malformations.
The project is led by a single SME, CYTO365 AB from Sweden, which maintains 100% industry control. This lean structure suggests a fast-track approach to commercialization, focusing heavily on manufacturing efficiency and COGS reduction rather than academic research.
Contact CYTO365 AB in Sweden for partnership or licensing inquiries.
Contact us to find similar medical device innovations for your portfolio.
